Skip to main content

Table 1 Patient characteristics at initial diagnosis for the total population and stratified by year of diagnosis before or after 2012

From: Guy’s and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database

Characteristics

Frequency

(n = 788)

Year of diagnosis

p-value

< 2012

> 2012

Age at diagnosis (years)

 Mean (±SD)

62 (±7.6)

61.4 (±7.2)

61.7 (±7.8)

 

 Median (IQR)

63 (57–67)

63 (57–63)

62 (56–67)

 

Age at diagnosis (years)

   

0.86

 

n (%)

   

  ≤ 65

 496 (62.9)

289 (64.1)

207 (64.7)

 

  > 65

275 (34.9)

162 (35.9)

113 (35.3)

 

  < 50

59 (7.5)

 

 50–59

219 (27.7)

 

 60–69

374 (47.3)

 

 70–80

119 (15.0)

 

 Unrecorded

17 (2.2)

 

Year of Diagnosis

n (%)

457 (58.0)

331 (42.0)

  < 2009

107 (13.5)

 

 2009–2011

261 (33.0)

 

 2012–2014

296 (37.4)

 

 2015–2018

124 (15.7)

 

Ethnicity

n (%)

n = 669

0.04

 Caucasian

472 (59.7)

319 (74.2)

152 (63.6)

 

 Black African

107 (13.5)

59 (13.7)

48 (20.1)

 

 Black Caribbean

69 (8.6)

40 (9.3)

29 (12.1)

 

 Asian

22 (2.8)

12 (2.8)

10 (4.2)

 

 Unrecorded

119 (15.1)

 

PSA level

(ng/mL)

  

0.001

 Mean (±SD)

6.6 (± 3.4)

6.4 (±3.3)

6.9 (±3.5)

 

 Median (IQR)

6 (4.4–8.0)

6.0 (4.0–8.7)

6.29 (4.7–8.2)

 

PSA level (ng/mL)

n (%)

n = 718

0.09

 0–5

273 (34.6)

173 (40.8)

100 (34.0)

 

 5 .1–10

350 (44.4)

193 (45.5)

157 (53.4)

 

 10.1–15

74 (9.4)

48 (11.3)

26 (8.8)

 

 15.1–20

21 (2.7)

10 (2.4)

11 (3.7)

 

 Unrecorded

70 (8.9)

 

T Stage (at DRE)

n (%)

   

 Benign

331 (42.0)

 

 T2

176 (22.3)

 

Number having a diagnostic MRI

n (%)

  

0.001

 MRI at diagnosis

235 (29.8)

64 (14.0)

171 (51.7)

 

 Unrecorded

553 (70.2)

393 (86.0)

160 (48.3)

 

Diagnostic MRI T Stage

n = 235

  

 

n (%)

   

 T0

24 (10.2)

 

 T2

135 (57.4)

 

 Unrecorded

76 (32.3)

 

Method of diagnostic biopsy

n (%)

n = 708

0.12

 TP

254 (32.2)

141 (33.6)

113 (39.2)

 

 TRUS

422 (53.6)

263 (62.6)

159 (55.2)

 

 Othera

32 (4.1)

16 (3.8)

16 (5.6)

 

 Unrecorded

80 (10.2)

 

Gleason Score

n (%)

n = 730

0.75

  ≤ 3 + 3

595 (75.5)

357 (81.9)

238 (81.0)

 

 3 + 4

135 (17.1)

79 (18.1)

56 (19.1)

 

 Unrecorded

58 (7.4)

 

Number of cores taken

    

 Mean (±SD)

21.0 (±10.7)

 

 Median (IQR)

15 (12–32)

 

Number of cores taken

 

n (%)

n = 564

0.08

  < 12

37 (4.7)

19 (5.6)

18 (6.8)

 

 12–14

266 (33.8)

141 (41.3)

125 (47.0)

 

 15–24

80 (10.2)

49 (14.4))

31 (11.7)

 

  > 25

224 (28.4)

132 (38.4)

92 (34.6

 

 Unrecorded

181 (23.0)

 

Number of positive cores

 Mean (±SD)

2.3 (±2.1)

 

 Median (IQR)

2 (1–3)

 

Number of positive cores

n (%)

n = 611

0.02

 1

288 (36.6)

178 (52.4)

110 (40.6)

 

 2

129 (16.4)

64 (18.8)

65 (22.9)

 

 3

76 (9.6)

64 (12.4)

34 (12.6)

 

  > 3

118 (15.0)

56 (16.5)

62 (22.9)

 

 Unrecorded

177 (22.5)

 
  1. Statistical test: Pearson’s Chi squared
  2. PSA prostate specific antigen, MRI magnetic resonance imaging, DRE digital rectal exam, TP trans-perineal, TRUS trans-rectal ultrasound, SD standard deviation, IQR interquartile range
  3. aOther = HOLEP, TURP